News | July 28, 2021
Morepen to start Sputnik V Vaccine commercial production in 4-6 weeks
The first six batches are being shipped to the Gamaleya Center, Moscow for the quality approval
The first six batches are being shipped to the Gamaleya Center, Moscow for the quality approval
The first batch will be shipped to the Gamaleya Center for the quality control
India is expecting to manufacture 30-35 crore COVID-19 vaccines between July - August 2021
Cocktails of 2 mAbs based products are better equipped to deal with variants than single mAb based products which have a tendency of losing their efficacy with rapidly generating variants
Targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses from the date of start of commercial production
Financial support is being provided as a grant from the Government of India
The current production capacity of indigenously developed Covaxin vaccine will be doubled by May-June 2021 and then increased nearly 6-7 fold by July-August 2021.
Indian government is expecting pharmaceutical industry to fetch incremental sales worth Rs. 294,000 crore and exports up to Rs. 196,000 crore by FY 2027-28
_256_384.jpg)
Indian Chemical News, an online news media covering Pharma, Chemical and Petrochemical sector is organizing an E-conference on “India's Pharma Industry Outlook 2021” on 12th February, 2021 from 3:00 PM – 4:30 PM.
With a mix of vaccines targeting different stages of COVID-19, the company is eyeing huge market potential
Subscribe To Our Newsletter & Stay Updated
